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Inverse Correlation Between Plasma Adropin and ET-1 Levels
in Essential Hypertension
A Cross-Sectional Study
Xiaosong Gu, MD, PhD, Hui Li, MD, Xinyi Zhu, MD, Haibo Gu, MD, Jianchang Chen, MD, PhD,
Luchen Wang, BS, Pamela Harding, PhD, and Weiting Xu, MD
Abstract: Adropin is a recently identified bioactive protein that
promotes energy homeostasis by affecting glucose and lipid metab-
olism. Recently, adropin has also been reported to be associated with
endothelial dysfunction. Also, ET-1, as a biomarker for endothelial
dysfunction, is a key regulator in hypertension. Accordingly, the aim of
the present study was to detect the relationship between plasma adropin
and ET-1 levels in hypertension.
A total of 123 participants, diagnosed with primary hypertension on
the basis of World Health Organization criteria (systolic blood pressure
[SBP]140mmHg and/or diastolic blood pressure (DBP)90mmHg),
and 58 normotensive subjects were enrolled in the cross-sectional study
from October 2011 to December 2013. All study participants were older
than 18 years of age. Adropin and ET-1 levels were measured by
enzyme-linked immunosorbent assay (ELISA).
We found that plasma adropin levels were significantly lower in
hypertensives compared with controls (3.18 1.00 vs 4.21 1.14 ng/
mL, P< 0.001). Plasma ET-1 levels were higher in hypertensives than
controls (2.60 1.14 vs 1.54 0.66 pg/mL, P< 0.001). Adropin had a
negative correlation with DBP (r¼0.40, P< 0.001), SBP (r¼0.49,
P< 0.001), and adjusted for age, body mass index, SBP, DBP, glucose,
TC, TG, LDL, and Cr, there was a negative correlation between ET-1
and adropin (r¼0.20, P¼ 0.04). In multivariate logistic regression
analysis of the variables, ET-1 (odds ratio [OR], 3.84; 95% CI, 2.16–
6.81; P< 0.001) and adropin (OR, 0.99; 95% CI, 0.991.0; P< 0.001)
were found to be independent predictors for hypertension.
In conclusion, decreased plasma adropin levels are associated with
increased blood pressure in hypertension. Adropin is an independent
predictor for hypertension, and may influence blood pressure by pro-
tecting endothelial function.
(Medicine 94(40):e1712)
Abbreviations: BMI = body mass index, CKD = chronic kidney
disease, Cr = Creatinine, DBP = diastolic blood pressure, ET-1 =
Endothelin 1, LDL = low-density lipoprotein, OR = odds ratio,
SBP = systolic blood pressure, TC = total cholesterol, TG =
triglycerides.
INTRODUCTION
H ypertension contributes greatly to the global burden ofdisease and in many patients current treatments are often
inadequate. Endothelial dysfunction plays an important role in
the progression of hypertension.1 Endothelin-1 (ET-1) is elev-
ated in hypertensive subjects and is a potential marker of
endothelial dysfunction.2 ET-1 is a potent vasoconstrictor that
is implicated in the pathogenesis of hypertension,3,4 and
reduced ET-1 levels have been shown to decrease systolic
blood pressure (SBP).5 In the context of the strong association
between hypertension and chronic kidney disease (CKD),6 ET-
1 was also found to have a close relationship with renal
dysfunction induced by hypertension.7 Thus ET-1, as a bio-
marker for endothelial dysfunction, is a key regulator
in hypertension.
Endothelial dysfunction is an important manifestation of
diabetes. Increased production of ET-1 mediates many patho-
physiological events contributing to the development of vas-
cular complications in diabetes mellitus.8 Adropin, encoded by
the energy homeostasis-associated (ENHO) gene, participates
in the maintenance of energy homeostasis and the response to
insulin.9 Recently, adropin has also been reported to be associ-
ated with endothelial dysfunction.10 Low adropin concen-
trations correlate with endothelial dysfunction in diabetes
mellitus type 211 and the protective role of adropin has been
ascribed to the upregulation of endothelial NO synthase.10
However, whether adropin can mediate progression of patho-
physiological events by regulating ET-1 is still unclear.
In studies using obese pediatric patients, adropin was
found to have no relationship with blood pressure, whether
similar results would be found in adult hypertenisives is still
open to debate.12,13 However, another study indicated that
adropin likely has ability to regulate blood pressure.14 There-
fore, our study was designed to investigate plasma adropin
levels in essential hypertension, and to investigate the corre-
lation between adropin and ET-1 in these patients.
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METHODS
Subjects
A total of 123 participants, in total, were diagnosed
with primary hypertension in accordance with the World
Health Organization criteria (SBP140mmHg and/or diastolic
blood pressure (DBP) 90mmHg), and were enrolled in the
cross-sectional study. These patients were assessed, either, in
the clinic or the in-patient department of the Second Affiliated
Hospital of Soochow University (Suzhou, China) from October
2011 to December 2013. Exclusion criteria were established on
the presence of any one of the following: secondary hyperten-
sion or antihypertensive medication; diabetes; hyperlipidemia;
kidney dysfunction; liver disease; lung disease; and cancer.
Secondary hypertension was barred from the study on the basis
of clinical and biochemical assessments. In parallel, 58 normo-
tensive subjects were assessed in the same hospital and enrolled
as a control group, using the same exclusion criteria. All study
participants were older than 18 years.
Ethical and Legal Issues
The experimental protocol was in accordance with the
Declaration of Helsinki (2008) of the World Medical Associ-
ation, was approved by the ethics committee of the Second
Affiliated Hospital of Soochow University. All subjects pro-
vided written informed consent before participating in the study.
Clinical and Biochemical Assessment
The electronic medical records were reviewed to obtain
demographic and clinical data. The patients’ body mass index
(BMI) was calculated by dividing their weight in kilograms by
their height in meters squared. Blood pressure was measured,
using an automatic BP monitor, in the sitting position, using the
right upper arm and an appropriately sized cuff, measurements
were performed three times in the participant’s right arm with a 2-
minute interval, after a rest period of at least 5 minutes. Hyper-
lipidemia was categorized as a total cholesterol (TC) concen-
tration >5.69mmol/L, triglyceride (TG) concentration
>1.7mmol/L, low-density lipoprotein (LDL) concentration
>3.1mmol/L, and/or the presence of cholesterol-lowering medi-
cation. All venous blood samples were collected after an over-
night fasting routine. Blood biochemical parameters (fasting
plasma glucose, total cholesterol, TG, and plasma creatinine
[Cr] concentration) were performed using an AU5400 automated
chemistry analyzer (Beckman Coulter, Fullerton, CA) on the
same day of blood collection. LDL cholesterol was indirectly
measured using the Friedewald formula. To separate plasma,
other venous blood samples were collected into tubes with
EDTA2Na (1mg/mL), aprotinin (500U/mL) (Becton Dickinson,
Franklin Lakes, NJ), and then centrifuged at 1500g at 48C for
15min. The prepared plasma samples stored at 808C until use.
Plasma adropin concentrations were measured using the adropin
ELISA kit (catalog no. EK-032-35; Phoenix pharmaceuticals Inc.,
Burlingame, CA), according to the manufacturer’s instructions.
The detection range of this kit is 0.01 to 100ng/mL and the
sensitivity is 0.3 ng/mL. Circulating ET-1 concentrations were
determined using the ET-1 (human) ELISA kit (catalog no.
QET00B; R&D Systems, Minneapolis, MN) according to the
manufacturer’s instructions. The detection range for this kit is
0.34 to 250pg/mL and its sensitivity is 0.102pg/mL.
Statistical Analysis
Data were analyzed using SPSS software (version 22.0;
SPSS, Inc., Chicago, IL). Continuous data are expressed as the
meanSD, categorical variables are expressed as a percentage,
and values of P< 0.05 are considered statistically significant. A
2-group student t test with a 0.05 2-sided significance level will
have 80% power to detect an effect size of 0.45 when the sample
sizes in the 2 groups are 58 and 123. The difference between the
2 continuous variables was studied using the Student t test, and
the difference between categorical variables was applied using
the x2 test. Correlation relationships were performed using
Pearson coefficient of correlation. Multivariable logistic
regression analyses were used to access the association of
various determinants with hypertension, the final multivariable
model was selected using backward selection, all variables in
the final model are significant P< 0.05.
RESULTS
Clinical and Laboratory Characteristics of the
Study Participants
A total of 123 patients with newly established hypertension
and 58 health controls were included in the study. The demo-
graphic characteristics are described in Table 1. Patients with
hypertension had a higher DBP and SBP than healthy controls
(DBP: 85.3 15.5 vs 70.8 8.3mmHg, p< 0.001; SBP:
164.2 16.7 vs 112.5 12.1mmHg, P< 0.001). There were
no significant differences in terms of age, sex, smoking status,
glucose, TG, TC, and LDL between hypertensive subjects and
healthy controls. Plasma ET-1 was significantly higher in hyper-
tensive subjects than in controls (2.60 1.14 vs 1.54 0.66pg/
mL, P< 0.001), whereas adropin levels were lower in hyperten-
sive subjects compared with controls (3.18 1 vs 4.21 1.14ng/
mL, P< 0.001). Even excluding patients with kidney dysfunction,
hypertensive subjects had higher Cr than controls (65.98 11.64
vs 61.60 13.43mmol/L, P< 0.05).
Correlation Between Adropin and Other Clinical
Characteristics in Hypertension
As demonstrated in Table 2, plasma adropin levels were
negatively correlated with DBP (r¼0.40, P< 0.001), SBP
TABLE 1. Clinical and Biochemical Characteristics of the 123
Hypertensive Patients and 58 Healthy Controls
Healthy Con-
trols (n¼ 58)
Hypertension
(n¼ 123) P
Age, y 60.5 11.4 64.0 11.4 0.06
Sex (M/F) 34/24 64/59 0.43
Smoke 10(17.2%) 31(25.2%) 0.26
BMI, kg/m2 22.24 3.2 23.50 2.67 0.01
SBP, mmHg 112.5 12.2 164.2 16.7 <0.001
DBP, mmHg 70.7 8.3 85.3 15.5 <0.001
Glucose, mmol/L 4.58 0.77 4.69 0.71 0.34
TC, mmol/L 4.26 1.11 4.19 0.94 0.71
LDL, mmol/L 2.41 0.87 2.36 0.80 0.73
TG, mmol/L 1.58 0.68 1.63 0.78 0.67
Cr, mmol/L 61.60 13.43 65.98 11.64 0.04
Adropin, ng/mL 4.21 1.14 3.18 1.0 <0.001
ET-1, pg/mL 1.54 0.66 2.60 1.14 <0.001
P< 0.05 was considered to be statistically significant. BMI¼ body
mass index, Cr¼ creatinine, DBP¼ diastolic blood pressure, ET-
1¼ endothelin 1, LDL¼ low-density lipoprotein, SBP¼ systolic blood
pressure, TC¼ total cholesterol, TG¼ triglycerides.
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(r¼0.49, P< 0.001), and BMI (r¼0.27, P< 0.001) in 123
hypertensive patients. However, plasma adropin levels did not
correlate with glucose (r¼ 0.14, P¼ 0.06) or Cr levels
(r¼0.11, P¼ 0.13). ET-1 was positively correlated with
DBP (r¼ 0.40, P< 0.001) and SBP (r¼ 0.51, P< 0.001). When
adjusted for age, BMI, SBP, DBP, Glucose, TC, TG, LDL, and
Cr, there was a negative correlation between ET-1 and adropin
(r¼0.20, P¼ 0.04) (Figure 1).
Multivariate Regression Analysis
Multivariate logistic regression analysis was run with the
variables (age, sex, smoking, glucose, TC, TG, LDL, Cr) in all
181 participants. The final model included only ET-1 and
adropin. ET-1 (odds ratio [OR], 3.84; 95% confidence interval
[CI], 2.16–6.81; P< 0.001) and adropin (OR, 0.99; 95% CI,
0.99–1.0; P< 0.001) were independent predictors of hyperten-
sion (Table 3). Controlling for adropin, for every 1-pg/mL
increase in ET-1, the odds of having hypertension increase
by 3.84. Likewise, controlling for ET-1, for every 1ng/ml
increase in adropin the odds of having hypertension decrease
by 0.99.
DISCUSSION
In this paper, we first show that in the hypertension group,
plasma adropin levels are lower than that of healthy controls.
Secondly, decreasing adropin is negatively correlated with
blood pressure in hypertensive patients. After adjusting for
age, BMI, DBP, SBP, glucose, TC, TG, LDL and Cr, decreasing
plasma adropin levels continued to be associated with increas-
ing ET-1 levels. Lastly, we report that adropin and ET-1 are
independent predictors of hypertension. Thus, the current study
suggests an independent link between adropin and endothelial
dysfunction in hypertension.
Given the significant impact hypertension has on the
global burden of disease, investigating the risk factors and
underlying mechanisms of hypertension will shed light on
new methods of therapy. ET-1 is a potential vasoconstrictor
that is involved not only in the pathogenesis of essential
hypertension, but also in progression of chronic kidney disease
secondary to hypertension.15–17 ET-1 is a peptide originally
isolated from the supernatants of cultured endothelial cells and
it exerts a wide variety of biological effects on different tissues,
including the vascular wall. Hypertensive patients have a higher
ET-1 than healthy controls.18 Circulating levels of ET-1 and
endogenous ET(A)-mediated constriction are increased in
human aging.19 ET-1 is also involved in progression of renal
hypertension. In CKD, activation of the ET system seems to
contribute not only to increased blood pressure but also to loss
of nocturnal blood pressure dipping.7 Clinical trials have
addressed the use of ET receptor antagonists as monotherapy
in primary hypertension, and as an add-on therapy in resistant
hypertension and CKD.6 Our study also shows ET-1 to be
elevated in the hypertension group and with ET-1 having a
positive relationship with blood pressure. We show that ET-1 is
an independent risk factor for hypertension.
Previous studies show that certain energy adipokine reg-
ulators such as adiponectin and leptin have an effect on blood
pressure by regulating endothelial function and the central
nervous system.20,21 As a new adipokine energy regulator,
whether adropin has the same kind of effect is a question that
warrants further investigation. In our study, we find that adropin
is negatively correlated with blood pressure and is an indepen-
dent risk factor for hypertension. Because adropin can be
influenced by BMI, glucose, and TGs,22 we adjusted for these
parameters, and continued to find a negative correlation
between adropin and ET-1. Out results suggest that adropin
may influence blood pressure by promoting endothelial dys-
function. Findings from several articles support our results.
Lovren et a10 have reported that one of the endothelial protec-
tive actions of adropin is likely mediated via upregulation of
endothelial NO synthase and that in patients with obstructive
TABLE 2. Pearson Analysis of ET-1 and Adropin With Other
Parameters in Hypertension
ET-1 Adropin
r p r p
Age, y 0.07 0.36 0.02 0.81
BMI, kg/m2 0.17 0.02 0.27 <0.001
SBP, mmHg 0.51 <0.001 0.49 <0.001
DBP, mmHg 0.39 <0.001 0.40 <0.001
Glucose, mmol/L 0.07 0.32 0.14 0.06
TC, mmol/L 0.39 0.6 0.08 0.29
LDL, mmol/L 0.04 0.6 0.10 0.18
TG, mmol/L 0.01 0.92 0.01 0.90
Cr, mmol/L 0.06 0.42 0.11 0.13
P< 0.05 was considered to be statistically significant. BMI¼ body
mass index, Cr¼Creatinine, DBP¼ diastolic blood pressure, ET-
1¼Endothelin 1, LDL¼ low-density lipoprotein, SBP¼ systolic blood
pressure, TC¼ total cholesterol, TG¼ triglycerides.
FIGURE 1. The relationship between adropin and endothelin 1
(ET-1) in hypertension subjects. Adropin showed significant cor-
relation with ET-1 (r¼0.20, P¼0.04).
TABLE 3. Multivariable Logistic Regression Analysis of Factors
Correlated With Hypertension in the 58 Healthy Participants
and the 123 Hypertensive Patients
Variables Odds Ratio 95% Confidence Interval P
ET-1 3.84 2.16–6.81 <0.001
Adropin 0.99 0.99–1.0 <0.001
P< 0.05 was considered to be statistically significant in the multi-
variate logistic regression analysis. ET-1¼ endothelin 1.
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sleep apnea, a significant risk factor for hypertension, adropin
concentration is a reliable indicator of endothelial dysfunc-
tion.23 Lower serum adropin levels are also associated with
cardiac syndrome X (CSX), and endothelial dysfunction is
involved in the pathophysiology of CSX.24 In individuals with
type 2 diabetes, adropin is an independent risk factor for
endothelial dysfunction.11 In the context of these studies, we
conclude from our results that adropin influences blood pressure
by protecting endothelial function.
It is possible that there are other mechanisms by which
adropin affects blood pressure. Our study does not show the
relationship between adropin and the autonomic nervous
system. However, it has been demonstrated that adropin
has increased expression in the brain in diabetic rats, and
that adropin knockout mice exhibited decreased locomotor
activity and impaired motor coordination coupled with defec-
tive synapse formation.25,26 Thus adropin may be a regulator
of nervous system activity. Whether adropin can influence
blood pressure by regulating the central automatic nervous
system is a question remains to be studied.
In our study, the hypertension group had higher Cr and
lower adropin levels compared with the control group. Because
adropin has a low molecular weight of about 5Kda,27 and the
normal urine adropin concentration were found to be approxi-
mately 4 times higher than that of corresponding serum adropin
concentration.14 Moreover, glomerular perfusion pressure and
molecular weight are 2 important determinants for protein to
pass through the glomerular filtration barrier. Thus, in hyper-
tensive patients, it is possible that adropin is more easily
filtered and may therefore be lower in plasma. In our protocol,
we excluded patients with kidney dysfunction, but we con-
tinued to observe an appreciable difference in plasma Cr
between the hypertensive and control group. It is well known
that the kidney has a large functional reserve, with rises in Cr
virtually undetectable in early renal dysfunction. Increased
protein filtration and decreased protein reabsorption are 2
characteristics of renal dysfunction. Thus, decreased adropin
reabsorption may also account for our results. Kuloglu and
Aydin28 reported that adropin and iNOS immunoreactivity
were co-localized to the glomeruli, peritubular interstitial cells
and peritubular capillary endothelium of the cortex. Because
adropin is highly expressed in the kidney,25 it may play a
role in compensatory mechanisms against renal damage
inflicted by diabetes. Whether adropin has a true role in
hypertension or is an artifact of renal dysfunction remains to
be fully elucidated.
Our study has several limitations. First, our study sample is
relatively small, the survey was mainly carried out at a single
site, and selection bias might be present, which may restrict the
application of the results to broader populations. Second,
although our study shows that adropin has a relationship with
blood pressure and is an independent risk factor for hyperten-
sion, whether the correlation beween blood pressure and adro-
pin represents a true cause-and-effect relationship or merely
reflects parallel changes because of a common underlying
etiology in this population needs to be further clarified. Con-
firmation that alteration of adropin is a major risk factor for
hypertension may require investigation using adropin trans-
genic overexpression mice models, or systemic treatment using
recombinant adropin.
In conclusion, adropin is a risk factor for hypertension;
it has a negative relationship with blood pressure and
regulates blood pressure by possibly influencing endothelial
function.
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